An observational study in Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, sponsored by Dong-A University Hospital. Status unknown. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-08-10.
Sponsored by Dong-A University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Research question: Is KRd therapy effective and safe in the real-world Asian patients?
Primay objective: To evaluate the effectiveness of KRd in RRMM patients
Secondary objectives:
To evaluate the effectiveness of investigational treatment strategy by
Key study variables:
Demographic data, ISS, R-ISS, cytogenetic abnormalities on FISH and G-banding, previous treatment regimens, response to previous treatment regimens, existence of extramedullary plasmacytoma, MM-related symptoms, whether or not M protein has increased twice or more in 2-3 months at the time of KRd commencement, response to KRd therapy, duration of KRd treatment, adverse events during KRd therapy, disease progression and progression date, survival, and censored date or day of death
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
This study's planned enrollment of 300 is above the median of 150 across 486 observational studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →Dong-A University Hospital is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Relapsed and/or refractory multiple myeloma patients treated with carfilzomib-lenalidomide-dexamethasone combination chemotherapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Multiple myeloma in relapsed but not refractory, relapsed and refractory, and primary refractory status
Drug: Carfilzomib · Drug: Lenalidomide · Drug: Dexamethasone
Intravenous carfilzomib, lenalidomide, dexamethasone
Also known as: Kyprolis
Oral
Also known as: Revlimid
Oral or intravenous
Progression-free survival
the time from the first date of KRd to the date of disease progression or death or censored date
Time frame: up to 54 months
Overall survival
the time from the first date of KRd treatment to the time of death or censored date
Time frame: up to 54 months
Overall response rate, clinical benefit rate
the proportion of patients who achieved a PR or better, which response is defined by the IMWG criteria, the proportion of patients who achieved a MR or better
Time frame: up to 54 months
Duration of response
the time from the first date of response to the time of disease progression or death or censored date
Time frame: up to 54 months
Toxicity profile
toxicities as determined by the incidence of clinical and laboratory findings occurred from the time of the first date of KRd treatment to the date of disease progression or death or censored date
Time frame: up to 2 years
No study locations are listed for this record.
Plan to share: No
Start is estimated for Aug 2022; primary completion for Jan 2023, 5 months later.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dong-A University Hospital